Sight Sciences, Inc. (SGHT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Sight Sciences, Inc. is an ophthalmic medical device company operating in two segments: Surgical Glaucoma (OMNI and SION products) and Dry Eye (TearCare System). The company is classified as an emerging growth company and a smaller reporting company. As of October 31, 2025, there were 52,871,731 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $19,906 | $20,157 | $56,978 | $60,792 |
| Gross Profit | $17,197 | $16,907 | $48,878 | $51,724 |
| Gross Margin | 86.4% | 83.9% | 85.8% | 85.1% |
| Operating Loss | $(7,905) | $(11,229) | $(33,430) | $(38,603) |
| Net Loss | $(8,169) | $(11,066) | $(34,264) | $(39,661) |
| Cash & Equivalents | $92,373 | $118,564 | As of Sept 30, 2025 | |
| Long-Term Debt (Net) | $40,069 | $39,356 | As of Sept 30, 2025 | |
| Operating Cash Flow (9M) | $(27,867) | $(18,892) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 1.2% QoQ and 6.3% YoY (9M). The Dry Eye segment saw a significant 87.7% drop in Q3 revenue ($0.2M vs $1.5M) due to lower SmartLid volumes following a price increase in late 2024 and a strategic shift toward securing reimbursement. Surgical Glaucoma revenue increased 5.8% QoQ but declined 1.9% YoY (9M) due to Medicare restrictions on combining MIGS procedures with cataract surgery.
- Cost Reductions: Operating expenses decreased 10.8% QoQ and 8.9% YoY (9M). This was driven by a restructuring initiative in Q3 2025 that reduced the global workforce by approximately 20%, incurring $2.8 million in one-time costs ($1.8M SG&A, $1.0M R&D). Stock-based compensation also decreased significantly.
- Margin Improvement: Despite revenue headwinds, gross margin improved to 86.4% in Q3 2025 (from 83.9% in Q3 2024) due to higher average selling prices in the Glaucoma segment, partially offset by tariff costs on products manufactured in China.
- Debt Amendment: In September 2025, the company amended its Hercules Loan Agreement to extend the interest-only period by six months (to Feb 1, 2027) and reallocate $10M of unavailable tranche funds to the interest-only period.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring net losses for the foreseeable future. They anticipate Dry Eye demand will increase in Q4 2025 following the establishment of Medicare pricing by two MACs (Novitas and FCSO) effective retroactively to Jan 1, 2025. Surgical Glaucoma margins are expected to remain under pressure from U.S. tariffs on Chinese imports.
- Liquidity: The company holds $92.4 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months. However, failure to improve revenue or control costs could necessitate additional equity or debt financing.
- Key Risks:
- Reimbursement: Ongoing uncertainty regarding Medicare and commercial payer coverage for Dry Eye products and restrictions on MIGS combination procedures for Glaucoma products.
- Supply Chain & Tariffs: Reliance on a single-source manufacturer in China exposes the company to significant tariff risks, which have already increased COGS by $0.6M in the first nine months of 2025.
- Legal Proceedings: A pending patent infringement lawsuit against Alcon and Ivantis regarding the Hydrus Microstent. While a $34M jury verdict was awarded in April 2024, the judgment is subject to appeal and potential invalidation via USPTO reexamination proceedings.
Investor Verification Checklist
- Reimbursement Status: Verify the extent of Medicare coverage expansion for TearCare beyond the two MACs (Novitas/FCSO) and the impact of the retroactive pricing on Q4 revenue recognition.
- Tariff Impact: Assess the company's progress in qualifying alternative manufacturing locations outside of China to mitigate the 10.35%+ tariff exposure on COGS.
- Legal Resolution: Monitor the status of the Alcon/Ivantis patent litigation and the USPTO reexamination proceedings, as the $34M verdict remains contingent.
- Debt Covenants: Confirm continued compliance with the Hercules Loan Agreement covenants, specifically minimum cash and revenue requirements, given the recent restructuring and revenue declines.
- Restructuring Savings: Evaluate whether the 20% headcount reduction and associated cost cuts are sufficient to offset the revenue decline and achieve a path to profitability.